You are here: Industry Insights > Market News

Market News

Alzheimer’s Disease: Charting the Course from Plaques to Promise Muhammad Farhan Khalid
May 28, 2025
New Tools，New Hope，New Frontier
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China PharmaSources
August 21, 2025
InnoCare Pharma announced today that the first patient has been dosed in the registrational trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) for patients with BTK inhibitor treated mantle cell lymphoma (MCL) in China.
Lepu Biopharma (2157.HK) announces 2025 interim results ACN Newswire
August 21, 2025
Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025.
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth PRNewswire
August 21, 2025
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.
Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum Henlius
August 20, 2025
Recently, Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with GeneQuantum Healthcare (Suzhou) Co., Ltd. ("GeneQuantum").
InnoCare Releases 2025 Interim Results and Business Highlights PharmaSources
August 20, 2025
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025.
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle ACN Newswire
August 20, 2025
In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen.
NUZ-001 OLE Study Demonstrates Long-Term Safety and Efficacy Signals Biotech Newswire
August 20, 2025
Neurizon? Therapeutics Limited is pleased to report positive topline results from the Open-Label Extension study of its lead candidate NUZ-001, for the treatment of amyotrophic lateral sclerosis , the major form of motor neurone disease.
Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning PRNewswire
August 20, 2025
Sisram Medical Ltd announced its unaudited consolidated interim results for the six months ended June 30, 2025 (the "Reporting Period").
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies ACN Newswire
August 02, 2025
Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash.